Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab

References

• Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol.12, 574–581 (2000).
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S. Alemtuzumab. Expert Rev. Anticancer Ther.5, 39–51 (2005).
   PubMed Web of Science ®Google Scholar
• Dearden CE. Alemtuzumab in lymphoproliferative disorders. Rev. Clin. Exp. Hematol.6, 435–448 (2002).
   PubMedGoogle Scholar
• Willis F, Marsh JC, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Haematol.114, 891–898 (2001).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Foà R, Bezares RF et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia23, 1980–1988 (2009).
   PubMed Web of Science ®Google Scholar
• Christian BA, Lin TS. Antibody therapy for CLL. Semin. Hematol.45, 95–103 (2008).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Björkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki A, Robak T et al.Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol.25, 5616–5623 (2007).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol.15, 1567–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Rai KR, Coutre S, Rizzieri D et al. Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis. Blood98, 365a (2001).
   Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99, 3554–3561 (2002).
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol.23, 2971–2979 (2005).
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood103, 3278–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med.347, 452–453 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin. Lymphoma3, 105–110 (2002).
   PubMedGoogle Scholar
• Laurenti L, Piccioni P, Cattani P et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica89, 1248–1252 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma7, 125–130 (2006).
   PubMedGoogle Scholar
• Montillo M, Tedeschi A, Miqueleiz S et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol.24, 2337–2342 (2006).
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood46, 219–234 (1975).
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer48, 198–206 (1981).
   PubMed Web of Science ®Google Scholar
• Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin. Infect. Dis.34, 1094–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood87, 4990–4997 (1996).
   PubMed Web of Science ®Google Scholar
• Worth LJ, Thursky KA. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention. Leuk. Lymphoma.47, 2435–2436 (2006).
   PubMed Web of Science ®Google Scholar
• Ng AP, Worth L, Chen L et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica90, 1672–1679 (2005).
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br. J. Haematol.132, 3–12 (2006).
   PubMed Web of Science ®Google Scholar
• Lamba R, Carrum G, Myers GD et al. Cytomegalovirus (CMV) infection and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogenic stem cell transplantation with alemtuzumab. Bone Marrow Transpl.36, 797–802 (2005).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Ravandi F, Riehl T et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-therapy. Blood111, 1816–1819 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang YY, Cheung WWW, Leung AYH, Tse E, Au WY, Kwong YL. Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy. Leukemia23, 800–801 (2009).
   PubMed Web of Science ®Google Scholar
• Han XY. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J. Clin. Microbiol.45, 1126–1132 (2007).
   PubMed Web of Science ®Google Scholar
• Smolej L. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice? Blood112, 2167 (2008).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Foà R, Bezares RF et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia23, 1980–1988 (2009).
   PubMed Web of Science ®Google Scholar
• Cheung WW, Tse E, Leung AYH, Yuen KY, Kwong YL. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. Am. J. Hematol.82, 108–111 (2007).
   PubMed Web of Science ®Google Scholar